Marshall Wace, LLP P Lx Pharma Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$1.9 - $4.18 $76,292 - $167,843	40,154 New	40,154 $98,000
Q1 2022 May 16, 2022	SELL	$3.54 - $8.3 $39,237 - $91,997	-11,084 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.69 - $19.66 $349,464 - $893,429	-45,444 Reduced 80.39%	11,084 $89,000
Q3 2021 Nov 15, 2021	SELL	$12.22 - $21.28 $4.37 Million - $7.61 Million	-357,658 Reduced 86.35%	56,528 $1.09 Million
Q2 2021 Aug 13, 2021	BUY	$9.0 - $15.94 $1.34 Million - $2.37 Million	148,724 Added 56.02%	414,186 $5.72 Million
Q1 2021 May 17, 2021	BUY	$5.24 - $10.14 $1.39 Million - $2.69 Million	265,462 New	265,462 $2.4 Million

62.7K

Ticker PLXP
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 29,137,700
Description
PLx Pharma Inc. operates as a commercial-stage drug delivery platform technology company in the United States. The company's lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other asp...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.